RHD genotype and production of anti-D: clinical significance, donor exposures, and antibody duration
| Antibody specificity . | Concurrent Antibodies . | ID . | RH genotype . | DTR . | RBC exposures . | Antibody demon-stration (months) . | |||
|---|---|---|---|---|---|---|---|---|---|
| RHD . | RHCE . | ||||||||
| D+ patients lacking conventional RHD | |||||||||
| D (n = 7) | 292* | DAU4 | DAU4 | ce(48C) | ce(48C) | Yes | 2 | — | |
| 50 | DAU0 | DAU5 | ce(48C) | ce(48C) | Yes | 91 | 1 | ||
| 34 | DAU0 | Deleted D | ce(733G) | ce | Yes | 269 | 3 | ||
| E | 104 | DAU3 | DAU5 | ce(48C) | cE | No | 39 | 19 | |
| C | 214* | DAU0 | Weak partial 4.0 | ce(48C) | ce(48C,733G) | SS | 4 | — | |
| 117 | Weak partial 4.0 | Weak partial 4.0 | ce(254G) | ce(48C,733G) | No | 32 | 2 | ||
| 14 | DIVa-2 | DIIIa-CE(4-7)-D | ce | ceS | No | 181 | 1 | ||
| D+ patients with one or more conventional RHD | |||||||||
| D (n = 22) | 100 | RHD | DIIIa-CE(4-7)-D | ce(733G) | ceS | Yes | 98 | 14 | |
| 141* | RHD | DIIIa-CE(4-7)-D | ce(733G) | ceS | No | 5 | 36 | ||
| S | 44 | RHD | DIIIa-CE(4-7)-D | ce | ceS | No | 116 | 1 | |
| 94 | RHD | DIIIa-CE(4-7)-D | ce | ceS | No | 82 | 16 | ||
| C | 138 | RHD | DIIIa-CE(4-7)-D | Ce | ceS | Yes | 103 | 5+ | |
| 110 | RHD | Weak partial 4.0 | Ce | ceS | Yes | 28 | 3 | ||
| 72 | RHD | DIVa-2 | ceTI | ceTI | No | 111 | 1 | ||
| E | 28 | RHD | DAU0 | ceHAR | ce(48C) | No | 212 | 1 | |
| 30 | RHD | DAU0 | Ce | ce(48C) | No | 177 | 1 | ||
| 99 | RHD | Deleted D | Ce | cE | Yes | 28 | 7 | ||
| 17 | RHD | Deleted D | cE | ce | No | 331 | 1 | ||
| 95 | RHD | Deleted D | Ce | ceTI | No | 155 | 4 | ||
| E | 95 | RHD | Deleted D | Ce | ceTI | Yes | 369 | 1 | |
| 21 | RHD | Deleted D | Ce | ce(733G) | No | 426 | 1 | ||
| 78 | RHD | Deleted D | ce(733G) | ce(254G) | Yes | 199 | 1 | ||
| 19 | RHD | RHD | ce | ce | No | 733 | 1 | ||
| 18 | RHD | RHD | cE | ce | No | 64 | 54 | ||
| 41 | RHD | RHD | ce | ce(733G) | Yes | 429 | 6 | ||
| 145 | RHD | RHD | Ce | ce(733G) | Yes | 48 | 1 | ||
| C | 20 | RHD | RHD | ce | ce(733G) | No | 224 | 1 | |
| 69 | RHD | RHD | ce(733G) | ce(733G) | No | 230 | 1 | ||
| C | 77 | RHD | RHD | ce | ce(254G) | Yes | 12 | 5 | |
| 103 | RHD | RHD | ce(48C) | ceS | — | — | — | ||
| D− patient | |||||||||
| D | 10 | Deleted D | Inactive RHD ψ | ce(254G) | ce(48C) | No | 314 | 112+ | |
| Antibody specificity . | Concurrent Antibodies . | ID . | RH genotype . | DTR . | RBC exposures . | Antibody demon-stration (months) . | |||
|---|---|---|---|---|---|---|---|---|---|
| RHD . | RHCE . | ||||||||
| D+ patients lacking conventional RHD | |||||||||
| D (n = 7) | 292* | DAU4 | DAU4 | ce(48C) | ce(48C) | Yes | 2 | — | |
| 50 | DAU0 | DAU5 | ce(48C) | ce(48C) | Yes | 91 | 1 | ||
| 34 | DAU0 | Deleted D | ce(733G) | ce | Yes | 269 | 3 | ||
| E | 104 | DAU3 | DAU5 | ce(48C) | cE | No | 39 | 19 | |
| C | 214* | DAU0 | Weak partial 4.0 | ce(48C) | ce(48C,733G) | SS | 4 | — | |
| 117 | Weak partial 4.0 | Weak partial 4.0 | ce(254G) | ce(48C,733G) | No | 32 | 2 | ||
| 14 | DIVa-2 | DIIIa-CE(4-7)-D | ce | ceS | No | 181 | 1 | ||
| D+ patients with one or more conventional RHD | |||||||||
| D (n = 22) | 100 | RHD | DIIIa-CE(4-7)-D | ce(733G) | ceS | Yes | 98 | 14 | |
| 141* | RHD | DIIIa-CE(4-7)-D | ce(733G) | ceS | No | 5 | 36 | ||
| S | 44 | RHD | DIIIa-CE(4-7)-D | ce | ceS | No | 116 | 1 | |
| 94 | RHD | DIIIa-CE(4-7)-D | ce | ceS | No | 82 | 16 | ||
| C | 138 | RHD | DIIIa-CE(4-7)-D | Ce | ceS | Yes | 103 | 5+ | |
| 110 | RHD | Weak partial 4.0 | Ce | ceS | Yes | 28 | 3 | ||
| 72 | RHD | DIVa-2 | ceTI | ceTI | No | 111 | 1 | ||
| E | 28 | RHD | DAU0 | ceHAR | ce(48C) | No | 212 | 1 | |
| 30 | RHD | DAU0 | Ce | ce(48C) | No | 177 | 1 | ||
| 99 | RHD | Deleted D | Ce | cE | Yes | 28 | 7 | ||
| 17 | RHD | Deleted D | cE | ce | No | 331 | 1 | ||
| 95 | RHD | Deleted D | Ce | ceTI | No | 155 | 4 | ||
| E | 95 | RHD | Deleted D | Ce | ceTI | Yes | 369 | 1 | |
| 21 | RHD | Deleted D | Ce | ce(733G) | No | 426 | 1 | ||
| 78 | RHD | Deleted D | ce(733G) | ce(254G) | Yes | 199 | 1 | ||
| 19 | RHD | RHD | ce | ce | No | 733 | 1 | ||
| 18 | RHD | RHD | cE | ce | No | 64 | 54 | ||
| 41 | RHD | RHD | ce | ce(733G) | Yes | 429 | 6 | ||
| 145 | RHD | RHD | Ce | ce(733G) | Yes | 48 | 1 | ||
| C | 20 | RHD | RHD | ce | ce(733G) | No | 224 | 1 | |
| 69 | RHD | RHD | ce(733G) | ce(733G) | No | 230 | 1 | ||
| C | 77 | RHD | RHD | ce | ce(254G) | Yes | 12 | 5 | |
| 103 | RHD | RHD | ce(48C) | ceS | — | — | — | ||
| D− patient | |||||||||
| D | 10 | Deleted D | Inactive RHD ψ | ce(254G) | ce(48C) | No | 314 | 112+ | |
DTR, DTR from Table 2; RBC exposures, cumulative number of RBC units transfused prior to antibody detection; antibody demonstration, number of months anti-D was detected. Additional antibody detected concurrently is indicated in the second column. SS, confounded by splenic sequestration; —, data not available; +, remains detectable; italicized patient demonstrates anti-D recurrence.
Episodically transfused.